118 related articles for article (PubMed ID: 11137555)
1. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment.
Hast R; Wallvik J; Folin A; Bernell P; Stenke L
Leuk Res; 2001 Jan; 25(1):13-18. PubMed ID: 11137555
[TBL] [Abstract][Full Text] [Related]
2. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
3. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
[TBL] [Abstract][Full Text] [Related]
4. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
Mohr B; Herrmann R; Huhn D
Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.
Hellström-Lindberg E
Br J Haematol; 1995 Jan; 89(1):67-71. PubMed ID: 7833279
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Perla G; Carella AM
Br J Haematol; 2003 Jul; 122(2):269-71. PubMed ID: 12846896
[TBL] [Abstract][Full Text] [Related]
9. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.
Terpos E; Mougiou A; Kouraklis A; Chatzivassili A; Michalis E; Giannakoulas N; Manioudaki E; Lazaridou A; Bakaloudi V; Protopappa M; Liapi D; Grouzi E; Parharidou A; Symeonidis A; Kokkini G; Laoutaris NP; Vaipoulos G; Anagnostopoulos NI; Christakis JI; Meletis J; Bourantas KL; Zoumbos NC; Yataganas X; Viniou NA;
Br J Haematol; 2002 Jul; 118(1):174-80. PubMed ID: 12100145
[TBL] [Abstract][Full Text] [Related]
10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
11. Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting.
Giordano G; Cutuli MA; Lucchesi A; Magnifico I; Venditti N; Vergalito F; Gasperi M; Di Marco R
Acta Haematol; 2020; 143(2):155-162. PubMed ID: 31533096
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns.
Lewinski UH; Floru S; Cohen AM; Mittelmann M
Leuk Lymphoma; 1994 Sep; 15(1-2):149-52. PubMed ID: 7858493
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
Stein RS; Abels RI; Krantz SB
Blood; 1991 Oct; 78(7):1658-63. PubMed ID: 1912554
[TBL] [Abstract][Full Text] [Related]
15. Treatment of myelodysplastic syndromes with recombinant human erythropoietin.
Hellström E; Birgegård G; Lockner D; Helmers C; Ost A; Wide L
Eur J Haematol; 1991 Nov; 47(5):355-60. PubMed ID: 1761122
[TBL] [Abstract][Full Text] [Related]
16. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.
Stasi R; Brunetti M; Terzoli E; Amadori S
Blood; 2002 Mar; 99(5):1578-84. PubMed ID: 11861271
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment.
Verhoef GE; Zachée P; Ferrant A; Demuynck H; Selleslag D; Van Hove L; Deckers F; Boogaerts MA
Ann Hematol; 1992 Jan; 64(1):16-21. PubMed ID: 1739754
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes.
Isnard F; Najman A; Jaar B; Fenaux P; Baillou C; Khoury E; Labopin M; Laporte JP; Woler M; Gorin NC
Leuk Lymphoma; 1994 Jan; 12(3-4):307-14. PubMed ID: 8167562
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
